AIM ImmunoTech signs manufacturing pact with Sterling Pharma, cost seen at $1.5 million
AIM•Sterling Pharma to manufacture additional PolyI and Poly C12U batches
AIM ImmunoTech entered a proposal agreement on July 31, 2026 with Sterling Pharma Solutions to manufacture additional PolyI and Poly C12U batches.
Work will be carried out at Sterling’s Dudley, UK site, including transfer of associated test methods to support Ampligen polymer precursor production.
Estimated cost is about $1.5 million, paid over 12 months.
Output is intended to support ongoing and future clinical trials, including a potential Phase 3 study in metastatic pancreatic cancer.
